Two commercial moves signaled accelerating activity in in‑vivo immune programming. Myeloid Therapeutics rebranded as Create Medicines and broadened its platform from myeloid programming to include T and NK cell programming using mRNA‑LNP delivery, aiming for off‑the‑shelf, redosable immunotherapies. Separately, Liberate Bio raised $31 million in seed funding from Khosla Ventures to advance an LNP platform for in‑body cell reprogramming. In‑vivo programming seeks to generate or modify therapeutic immune cells inside patients via RNA or vector delivery rather than ex vivo manufacturing. If safe and effective, the approach could reduce cost and time to treatment and enable scalable cell therapies for oncology and beyond.